SUNNYVALE, Calif., July 12 /PRNewswire-FirstCall/ -- Cepheid will be hosting an Analyst Reception on Tuesday, July 17, 2007 at the San Diego Marriott Hotel and Marina. Registration begins at 6:00 p.m. Pacific Time with a presentation and webcast beginning at 6:30 p.m. Pacific Time. This event is being held at the American Association for Clinical Chemistry (AACC) 2007 Annual Meeting in San Diego, Calif.
The purpose of the reception is to review a number of new products being introduced at the AACC meeting, including the new GeneXpert(R) Infinity Series of high-volume systems, 6-color multiplex capabilities for the entire GeneXpert family, Laboratory Information System (LIS) interface capabilities for the GeneXpert family, and the portable GX-I single module system.
Cepheid Chief Executive Officer, John Bishop, will discuss the strategic direction of the new systems. David Persing, Executive Vice President and Chief Medical and Technology Officer, will cover the company’s expanding pipeline of tests, and Rob Koska, Senior Vice President of Sales & Marketing, will discuss current marketing programs with a special focus on the MRSA initiatives.
Program agenda: Expanding the Reach of Molecular Diagnostics 6:00 p.m. PT Registration 6:30 p.m. PT Presentation and webcast John Bishop, Chief Executive Officer, Cepheid David Persing, M.D., Ph.D., Chief Medical and Technology Officer, Cepheid Robert Koska, Senior Vice President Sales and Marketing, Cepheid
A live webcast, along with accompanying presentation slides, may also be accessed on the Company’s web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentation will be available for 90 days. Web participants are encouraged to go to the web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.
About Cepheid
Cepheid , based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.
At the Company: John L. Bishop John R. Sluis CEO, Cepheid CFO, Cepheid 408-541-4191 408-541-4191 john.bishop@cepheid.comjohn.sluis@cepheid.com At Porter Novelli: Jason Spark 619-849-6005 jspark@pnlifesciences.com
Cepheid
CONTACT: John L. Bishop, CEO, john.bishop@cepheid.com, or John R. Sluis,CFO, john.sluis@cepheid.com, both +1-408-541-4191, of Cepheid; or JasonSpark of Porter Novelli, +1-619-849-6005, jspark@pnlifesciences.com, forCepheid
Web site: http://www.cepheid.com/
